Seagen Inc.

University of Minnesota

Seattle Genetics, Inc.

Nicole Okeley

Peter Senter

Dennis R Benjamin

Shyra Gardai

Vivian Trang

Gregory M Vercellotti

John D Belcher

Ryan Heiser

Noah Bindman

Divya Awasthi

Jessica Field

The invention relates to conjugates of biologically active compounds, wherein such a conjugate is comprised of a sequence of amino acids containing a tripeptide that confers selective cleavage by tumor tissue homogenate for release of free drug and/or improves biodistribution into the tumor tissue in comparison to normal tissue homogenate from the same species, wherein the normal tissue is the site of an adverse event associated with administration to a human subject in need thereof of a therapeutically effective amount of a comparator conjugate whose amino acid sequence is a dipeptide known to be selectively cleavable by Cathepsin B.

Selective drug release from internalized conjugates of biologically active compounds

Methods of producing T cells having reduced surface fucosylation and use thereof in adoptive cell therapy, in particular, in cancer treatment are provided.

T cells with reduced surface fucosylation and methods of making and using the same

The invention provides methods and compositions for the treatment of sickle cell disease and other inflammatory conditions.

Treatment of sickle cell disease and inflammatory conditions

Growing community of inventors

Bothell, WA, United States of America

Nicole Okeley